Agios Pharmaceuticals' Anemia ID offers no-cost genetic testing to patients in the United States with suspected hereditary anemias. The program is offered in partnership with PerkinElmer Genomics.
The program "provides a diagnosis confirming the underlying cause(s) of a patient’s hereditary anemia, supports the development of an effective management plan, informs genetic counseling discussions, and enables the identification of appropriate treatment options or clinical trials."
Read more about Anemia ID by visiting its website.
Posted 9/27/2021

By championing and encouraging advanced practice providers and allied health professionals to work at the top of their licenses, Wilmot Cancer Institute offers comprehensive care close to home through its breast care program that vastly improves the patient experience.

On the final day of the 43rd National Oncology Conference, a series of interactive panel discussions explored innovative strategies for remote patient monitoring across the globe, improving quality and safety amidst complex treatments, financial challenges in precision medicine and clinical trials, and more.

Day two of the 43rd National Oncology Conference featured lively panel discussions on operationalizing CAR T-cell therapy and bispecific antibodies, building sustainable supportive care services, expanding access amid rising patient volumes, as well as presentations from the six 2026 ACCC Innovator Award Winners.

Day one of ACCC’s 43rd National Oncology Conference featured a national look at financial advocacy, the Psychosocial Oncology Professionals Symposium, announcement of the President’s Theme from 2026-2027 ACCC President Douglas Flora, MD, LSSBB, FACCC, and recognition of the 2026 ACCC Innovators.
